Invited discussant abstracts 352O, 353O and LBA8
| Date | 28 September 2014 |
| Event | ESMO 2014 |
| Session | Breast cancer, metastatic |
| Topics | Cytotoxic agents Breast Cancer Therapy Biological therapy |
| Presenter | Hope Rugo |
| Authors |
H.S. Rugo
|
View the abstracts discussed:
- Efficacy and safety of maintenance bevacizumab (BEV) with or without capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mBC): IMELDA randomised phase III trial
- Efficacy and safety in TANIA, a randomised phase III trial of continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
- A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE)